Last $5.22 USD
Change Today -0.01 / -0.19%
Volume 80.0K
NBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 3:04 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robin L. Smith M.D., MBA,Ro

Executive Chairman and Chief Executive Officer, Neostem, Inc.
AgeTotal Calculated CompensationThis person is connected to 70 board members in 8 different organizations across 9 different industries.

See Board Relationships
49$1,235,500
As of Fiscal Year 2013

Background*

Dr. Robin L. Smith, M.D., MBA, Ro, has been Executive Chairman and Chief Executive Officer of Neostem, Inc. at Amorcyte, LLC and Progenitor Cell Therapy, LLC since June 2, 2006. Dr. Smith served as Chief Operating Officer - Ip2m Division and Senior Vice President - Ip2m Division at Dialog Group, Inc. Dr. Smith serves as Member of Advisory Board at Wellfleet Partners Investment Arm. They serves as Member of Medical Advisory Board at House of Brussels Chocolates Inc. They ...

Read Full Background

Corporate Headquarters*

420 Lexington Avenue
New York, New York 10170

United States

Phone: 212-584-4180
Fax: 646-514-7787

Board Members Memberships*

Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Nominating & Governance Committee
2006-Present
Executive Chairman and Chief Executive Officer

Education*

MD 1992
Yale University
MBA 1997
University of Pennsylvania - The Wharton School

Other Affiliations*

Annual Compensation*

Salary$495,000
Bonus$450,000
Total Annual Compensation$945,000

Stock Options*

All Other Compensation$40,782
Exercisable Options601,731
Unexercisable Options10,000
Total Number of Options611,731

Total Compensation*

Total Annual Cash Compensation$985,782
Total Short Term Compensation$945,000
Other Long Term Compensation$40,782
Total Calculated Compensation$1,235,500
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $5.23 USD 0.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Executive Officer
Athersys, Inc.
$568.8K
Michael D. West Ph.D.Chief Executive Officer, President and Director
BioTime, Inc.
$745.3K
Matthew T. Plavan Chief Executive Officer and Director
Cesca Therapeutics Inc.
$315.0K
Paul K. Wotton Ph.D.Chief Executive Officer, President, Director and Member of Pricing Committee
Advanced Cell Technology Inc.
--
Zami Aberman Executive Chairman and Chief Executive Officer
Pluristem Therapeutics, Inc.
$503.7K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.